Prevention of breast cancer: the case for studying inhibition of IGF-1 actions

被引:3
|
作者
Smith, J. [1 ]
Axelrod, D. [2 ]
Singh, B. [3 ]
Kleinberg, D. [1 ]
机构
[1] NYU, Inst Canc, Dept Med, New York, NY USA
[2] NYU, Inst Canc, Dept Surg, New York, NY USA
[3] NYU, Inst Canc, Dept Pathol, New York, NY USA
关键词
breast cancer; IGF-1; mammary development; pasireotide; raloxifene; SOM230; tamoxifen; FACTOR-I ACTION; GROWTH; CHEMOPREVENTION; TAMOXIFEN; RISK;
D O I
10.1093/annonc/mdq666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Measures to prevent breast cancer are receiving particular attention by women at high risk from either clinico-pathologic findings or genetic susceptibility. Life-style and nutritional interventions have been difficult to quantify, but merit further study. Chemoprevention with tamoxifen and subsequently with the related raloxifene demonstrates some efficacy, but may be not be applicable to premenopausal women (with regard to raloxifene), or have low acceptance (with regard to tamoxifen). Based on the importance of the insulin-like growth factor-1 pathway in mammary gland development, and the availability of a potent inhibitor, pilot studies are ongoing to evaluate such an inhibitor in women with demonstrable high risk to develop breast cancer. Short-term interventions with the inhibitor have been completed, and subsequent interventions are planned.
引用
收藏
页码:i50 / i52
页数:3
相关论文
共 50 条
  • [1] Evaluation of IGF-1 and IGF-1R in Triple Negative Breast Cancer
    Desai, S.
    Vora, A.
    Kurani, H.
    Nair, N.
    Sable, M.
    Shet, T.
    Gupta, S.
    Parmar, V.
    Badwe, R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 723 - 723
  • [2] Modulation of IGF-1 regulated breast cancer cell growth
    Horney, MJ
    Pettus, BJ
    Rosenzweig, SA
    MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 52 - 52
  • [3] INSULIN AND IGF-1 RECEPTORS IN HUMAN BREAST-CANCER
    VIGNERI, R
    BRAND, R
    GOLDFINE, ID
    PEZZINO, V
    RUSSO, P
    TRISCHITTA, V
    YAMAGUCHI, YF
    BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (02) : 166 - 167
  • [4] Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
    Ianza, Anna
    Sirico, Marianna
    Bernocchi, Ottavia
    Generali, Daniele
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [5] THE STRANGE CASE OF IGF-1
    Musaro, Antonio
    JOURNAL OF APPLIED PHYSIOLOGY, 2010, 108 (06) : 1826 - 1826
  • [6] DIFFERENTIAL ACTIONS OF GH VS. IGF-1
    Kopchick, J. J.
    GERONTOLOGIST, 2013, 53 : 505 - 505
  • [7] Inhibition of breast and prostate cancer cell growth by IGF-II ribozymes and IGF-1 receptor single chain antibodies.
    Fujita-Yamaguchi, Y
    Guo, N
    Wu, AM
    Rossi, JJ
    Li, SL
    FASEB JOURNAL, 1999, 13 (07): : A1467 - A1467
  • [8] Favorable outcome associated with an IGF-1 ligand signature in breast cancer
    Lina Mu
    David Tuck
    Dionyssios Katsaros
    Lingeng Lu
    Vincent Schulz
    Sudhir Perincheri
    Guido Menato
    Luca Scarampi
    Lyndsay Harris
    Herbert Yu
    Breast Cancer Research and Treatment, 2012, 133 : 321 - 331
  • [9] Favorable outcome associated with an IGF-1 ligand signature in breast cancer
    Mu, Lina
    Tuck, David
    Katsaros, Dionyssios
    Lu, Lingeng
    Schulz, Vincent
    Perincheri, Sudhir
    Menato, Guido
    Scarampi, Luca
    Harris, Lyndsay
    Yu, Herbert
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (01) : 321 - 331
  • [10] IGF-1 receptor inhibition by picropodophyllin in medulloblastoma
    Ohshima-Hosoyama, Sachiko
    Hosoyama, Tohru
    Nelon, Laura D.
    Keller, Charles
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 399 (04) : 727 - 732